Desmedt C, Ruíz-García E, André F
Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Eur J Cancer. 2008 Dec;44(18):2714-20. doi: 10.1016/j.ejca.2008.09.011. Epub 2008 Nov 1.
Breast cancer is characterised by a wide heterogeneity regarding outcome and drug sensitivity. A better prediction of these two parameters at the individual level should improve patient management and therefore also improve both the quality of life and the overall survival of the patient. Several molecular predictors for prognosis (MammaPrint or Oncotype DX) and drug prediction (DLD30, SET index) have been generated using DNA-based arrays or RT-PCR, some of these being tested in phase III trials. Although they exhibit good metric performance and should improve the quality of care in the next decade, these predictors are considered suboptimal regarding the potential of the technology. New study design and arrays should generate more powerful second generation gene signatures.
乳腺癌在预后和药物敏感性方面具有广泛的异质性。在个体水平上更好地预测这两个参数应能改善患者管理，从而提高患者的生活质量和总体生存率。已经使用基于DNA的阵列或逆转录聚合酶链反应（RT-PCR）生成了几种用于预后的分子预测指标（MammaPrint或Oncotype DX）和药物预测指标（DLD30、SET指数），其中一些正在III期试验中进行测试。尽管它们表现出良好的指标性能，并且在未来十年应能提高护理质量，但就该技术的潜力而言，这些预测指标被认为是次优的。新的研究设计和阵列应能产生更强大的第二代基因特征。
